These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10647656)

  • 1. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: long-term dropout parameters.
    Vardi Y; Sprecher E; Gruenwald I
    J Urol; 2000 Feb; 163(2):467-70. PubMed ID: 10647656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of success and risk factors for attrition in the use of intracavernous injection.
    Gupta R; Kirschen J; Barrow RC; Eid JF
    J Urol; 1997 May; 157(5):1681-6. PubMed ID: 9112505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy.
    Sexton WJ; Benedict JF; Jarow JP
    J Urol; 1998 Mar; 159(3):811-5. PubMed ID: 9474156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The causes of patient dropout from penile self-injection therapy for impotence.
    Mulhall JP; Jahoda AE; Cairney M; Goldstein B; Leitzes R; Woods J; Payton T; Krane RJ; Goldstein I
    J Urol; 1999 Oct; 162(4):1291-4. PubMed ID: 10492182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What nonresponse to intracavernous injection really indicates: a determination by quantitative analysis.
    Elhanbly S; Schoor R; Elmogy M; Ross L; Hegazy A; Niederberger C
    J Urol; 2002 Jan; 167(1):192-6. PubMed ID: 11743303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction.
    El-Sakka AI
    Int J Impot Res; 2006; 18(2):180-5. PubMed ID: 16163370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intracavernous auto-injection therapy with papaverine phentolamine via an auto-injection pen for patients with an erectile dysfunction: similar results achieved in family practice and urology].
    de Boer BJ; Lycklama a Nijeholt AA; Kleinjans HA
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):783-7. PubMed ID: 11346917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.
    Bechara A; Casabé A; Chéliz G; Romano S; Fredotovich N
    J Urol; 1996 Mar; 155(3):913-4. PubMed ID: 8583605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
    Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
    J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O; Hanani J; Shalhav A; Vardi Y; Goldwasser B
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.
    Raina R; Lakin MM; Agarwal A; Ausmundson S; Montague DK; Zippe CD
    Urology; 2004 Mar; 63(3):532-7; discussion 538. PubMed ID: 15028452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons for high drop-out rate with self-injection therapy for impotence.
    Weiss JN; Badlani GH; Ravalli R; Brettschneider N
    Int J Impot Res; 1994 Sep; 6(3):171-4. PubMed ID: 7735362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracavernous injection therapy for male erectile dysfunction.
    Fallon B
    Urol Clin North Am; 1995 Nov; 22(4):833-45. PubMed ID: 7483132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
    Perimenis P; Konstantinopoulos A; Perimeni PP; Gyftopoulos K; Kartsanis G; Liatsikos E; Athanasopoulos A
    Asian J Androl; 2006 Mar; 8(2):219-24. PubMed ID: 16491275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life.
    Sato Y; Tanda H; Kato S; Onishi S; Nitta T; Koroku M
    Int J Urol; 2007 Apr; 14(4):339-42; discussion 343. PubMed ID: 17470167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prostaglandin E1 (PGE1) in diagnosis and long-term therapy of erectile dysfunction].
    Derouet H; Weirauch A; Bewermeier H
    Urologe A; 1996 Jan; 35(1):62-7. PubMed ID: 8851852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostaglandin treatment in neurological patients with erectile dysfunction].
    Conejero Sugrañes J; Muñoz Villellas A; Sarrias Lorenz F; Ramírez Garceran L
    Arch Esp Urol; 2002; 55(1):63-8. PubMed ID: 11957754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.